Fair enough DJ,
Disclosure has been very poor. Had to be an insider to sell this knowing the production issues.
On the same note disclosure relating to positives like in vivo trial success with SC-1 wasn't released as a price sensitive announcement. To do the trial they must be producing SC-1? Maybe very small amounts compared to what is required in a human trial.
What company is doing this?
How many companies are evaluating this product?
Also there is some success with the CAR-T cell area, again which company are we dealing with?
Stock is behaving like a capital raising will be before any positive announcements.
At a guess what value would a successful SC-1 out licence be worth ?
Ann: Patrys Presents at AusBiotech Invest 2014, page-6
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $16.52K | 5.509M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 58473651 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 10774833 | 14 |
View Market Depth
| Last trade - 11.22am 07/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |